Free Trial
NASDAQ:CGTX

Cognition Therapeutics (CGTX) Stock Price, News & Analysis

Cognition Therapeutics logo
$0.30 -0.02 (-5.75%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.31 +0.01 (+3.07%)
As of 05/23/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Key Stats

Today's Range
$0.29
$0.32
50-Day Range
$0.30
$0.49
52-Week Range
$0.28
$2.58
Volume
347,097 shs
Average Volume
2.61 million shs
Market Capitalization
$18.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.13
Consensus Rating
Buy

Company Overview

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

CGTX MarketRank™: 

Cognition Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 517th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cognition Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cognition Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cognition Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cognition Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.82% of the float of Cognition Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cognition Therapeutics has recently increased by 0.11%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cognition Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cognition Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.82% of the float of Cognition Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cognition Therapeutics has recently increased by 0.11%, indicating that investor sentiment is decreasing.
  • Search Interest

    16 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 220% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.75% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cognition Therapeutics' insider trading history.
Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CGTX Stock News Headlines

Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Cognition Therapeutics presents results at AD/PD 2025 on CT1812
See More Headlines

CGTX Stock Analysis - Frequently Asked Questions

Cognition Therapeutics' stock was trading at $0.7013 at the beginning of 2025. Since then, CGTX shares have decreased by 57.7% and is now trading at $0.2969.
View the best growth stocks for 2025 here
.

Cognition Therapeutics, Inc. (NASDAQ:CGTX) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.02.

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share.

Top institutional investors of Cognition Therapeutics include Acadian Asset Management LLC (1.63%), Voss Capital LP (0.73%), CM Management LLC (0.65%) and Northeast Financial Consultants Inc (0.10%). Insiders that own company stock include Lisa Ricciardi, Peggy Wallace and Ellen B Richstone.
View institutional ownership trends
.

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cognition Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Eli Lilly and Company (LLY), Meta Platforms (META), GE Aerospace (GE), Arista Networks (ANET) and Celestica (CLS).

Company Calendar

Last Earnings
5/06/2025
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGTX
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.13
High Stock Price Target
$14.00
Low Stock Price Target
$1.50
Potential Upside/Downside
+1,963.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-25,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.76 per share
Price / Book
0.39

Miscellaneous

Free Float
32,927,000
Market Cap
$18.41 million
Optionable
Not Optionable
Beta
1.00
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CGTX) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners